Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.
Beth Y. Karlan MD
Advertisement
Articles by Beth Y. Karlan MD
Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer
Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Latest Updated Articles
Phase II AMG 386 and Paclitaxel Combination TrialApril 26th 2011
Dr. Karlan Describes AMG 386 Side EffectsApril 29th 2011
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5